Bennekou Susanne Hougaard, Allende Ana, Bearth Angela, Casacuberta Josep, Castle Laurence, Coja Tamara, Crépet Amélie, Hoogenboom Ron, Knutsen Helle, Lambré Claude, Nielsen Søren Saxmose, Turck Dominique, Civera Antonio Vicent, Villa Roberto, Zorn Holger, Castenmiller Jacqueline, Cheyns Karlien, Darney Keyvin, Gilbert Mary, Leblanc Jean-Charles, Meyer Haakon, Ntzani Evangelia, Paparella Martin, Vinceti Marco, Wallace Heather, Anastassiadou Maria, Bastaki Maria, Cattaneo Irene, Greco Luna, Lanzoni Anna, Riolo Francesca, Mosbach-Schulz Olaf, Terron Andrea, Halldorsson Thorhallur
EFSA J. 2025 Jul 22;23(7):e9478. doi: 10.2903/j.efsa.2025.9478. eCollection 2025 Jul.
This updated risk assessment evaluated evidence on potential adverse health effects of fluoride related to all sources of oral exposure as mandated by the European Commission. Fluoride benefit assessment was not included. Effects on the central nervous system, thyroid and bone were prioritised. Evidence from human studies indicates that total fluoride intake is associated with adverse effects on the developing brain at drinking water concentrations > 1.5 mg/L. The evidence of such associations below 1.5 mg/L was not sufficiently consistent to draw conclusions for risk assessment. Using drinking water concentration of 1.5 mg/L as a reference point, a safe level of intake including all sources of oral exposure of 3.3 mg/day was established for pregnant women to protect the fetus. This safe level of intake was extended to apply to other adults and children > 8 years. It is considered protective also against possible adverse effects on thyroid function and bone mineralisation, for which associations have been observed at water concentrations > 1.5 mg/L. Dental fluorosis was considered the most sensitive endpoint for children ≤ 8 years. Tolerable upper intake levels (UL) of 1.0, 1.6 and 2.0 mg/day were established for infants, toddlers and children 4-8 years, respectively. These ULs are considered protective against other possible adverse effects of fluoride, including neurodevelopmental outcomes. Aggregate exposure included intake of fluoride from food, drinking water, discretionary salt and (ingested) dental care products. Aggregate exposure based on the mean concentration of fluoride in EU drinking water (submitted data) was below the above health-based guidance values (HBGVs) for all age groups. Aggregate exposure exceeds the HBGVs at the 95th percentile of intake in the scenario of the P95 concentration of fluoride in EU drinking water, for all age groups except adolescents. The risk assessment suggests that the current legal limit for drinking water (1.5 mg/L) in the EU is not sufficiently protective.
根据欧盟委员会的要求,此次更新的风险评估对与所有口腔暴露源相关的氟化物潜在健康不良影响的证据进行了评估。未包括氟化物益处评估。重点关注了对中枢神经系统、甲状腺和骨骼的影响。人体研究证据表明,当饮用水中氟化物浓度>1.5毫克/升时,总氟摄入量与发育中的大脑的不良影响相关。低于1.5毫克/升时此类关联的证据不够一致,无法得出风险评估结论。以1.5毫克/升的饮用水浓度作为参考点,为保护胎儿,确定了包括所有口腔暴露源在内的孕妇安全摄入量为3.3毫克/天。这一安全摄入量范围扩大到其他成年人及8岁以上儿童。它也被认为对甲状腺功能和骨矿化的可能不良影响具有保护作用,在水浓度>1.5毫克/升时已观察到相关关联。氟斑牙被认为是8岁及以下儿童最敏感的终点指标。分别为婴儿、幼儿和4 - 8岁儿童确定了可耐受最高摄入量(UL),分别为1.0、1.6和2.0毫克/天。这些UL被认为可预防氟化物的其他可能不良影响,包括神经发育结果。总暴露量包括来自食物、饮用水、自由添加盐和(摄入的)口腔护理产品中的氟化物摄入量。根据欧盟饮用水中氟化物的平均浓度(提交的数据),所有年龄组的总暴露量均低于上述基于健康的指导值(HBGVs)。在欧盟饮用水中氟化物浓度处于第95百分位数(P95)的情况下,除青少年外的所有年龄组在摄入量的第95百分位数时总暴露量超过HBGVs。风险评估表明,欧盟目前的饮用水法定限值(1.5毫克/升)保护作用不足。